earnings
confidence high
sentiment negative
materiality 0.65
Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial
Atea Pharmaceuticals, Inc.
2022-Q2 EPS reported
-$0.88
- Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.
- Cash and equivalents $684.5M at June 30, 2022, down from $764.4M at Dec 31, 2021.
- Bemnifosbuvir to advance to global late-stage trial for COVID-19 in Q4 2022; primary endpoint hospitalization/death in high-risk patients.
- MORNINGSKY Phase 3 missed primary symptom alleviation endpoint but showed 71% reduction in hospitalization (exploratory p=0.047).
- AT-752 for dengue and HCV combo trial advancing; initial results expected Q4 2022.